These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9145968)

  • 1. Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer.
    Critz FA; Levinson K; Williams WH; Holladay D; Holladay C; Griffin V
    Urology; 1997 May; 49(5):668-72. PubMed ID: 9145968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques.
    Critz FA; Williams WH; Holladay CT; Levinson AK; Benton JB; Holladay DA; Schnell FJ; Maxa LS; Shrake PD
    Urology; 1999 Dec; 54(6):968-71. PubMed ID: 10604691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy.
    Critz FA; Levinson AK; Williams WH; Holladay CT; Griffin VD; Holladay DA
    J Urol; 1999 Apr; 161(4):1199-203; discussion 1203-5. PubMed ID: 10081869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation.
    Critz FA; Tarlton RS; Holladay DA
    Cancer; 1995 May; 75(9):2383-91. PubMed ID: 7536126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous radiotherapy for prostate cancer: 125I prostate implant followed by external-beam radiation.
    Critz FA; Levinson AK; Williams WH; Holladay CT; Griffin VD; Holladay DA
    Cancer J Sci Am; 1998; 4(6):359-63. PubMed ID: 9853134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer.
    Critz FA; Levinson AK; Williams WH; Holladay DA
    J Clin Oncol; 1996 Nov; 14(11):2893-900. PubMed ID: 8918485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer.
    Critz FA; Levinson AK; Williams WH; Holladay DA; Holladay CT
    Urology; 1997 Mar; 49(3):322-6. PubMed ID: 9123692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
    Lee WR; Hanlon AL; Hanks GE
    J Urol; 1996 Aug; 156(2 Pt 1):450-3. PubMed ID: 8683700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation.
    Stokes SH
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):129-36. PubMed ID: 10758314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition.
    Critz FA
    J Urol; 2002 Mar; 167(3):1310-3. PubMed ID: 11832720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to achieve a prostate specific antigen nadir of 0.2 ng./ml. after simultaneous irradiation for prostate cancer.
    Critz FA
    J Urol; 2002 Dec; 168(6):2434-8. PubMed ID: 12441934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml.
    D'Amico AV; Whittington R; Kaplan I; Beard C; Jiroutek M; Malkowicz SB; Wein A; Coleman CN
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1053-8. PubMed ID: 9169812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma.
    Ragde H; Elgamal AA; Snow PB; Brandt J; Bartolucci AA; Nadir BS; Korb LJ
    Cancer; 1998 Sep; 83(5):989-1001. PubMed ID: 9731904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.
    Zietman AL; Coen JJ; Shipley WU; Willett CG; Efird JT
    J Urol; 1994 Mar; 151(3):640-5. PubMed ID: 7508522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.
    Thames H; Kuban D; Levy L; Horwitz EM; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):929-43. PubMed ID: 14575823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.
    Shipley WU; Thames HD; Sandler HM; Hanks GE; Zietman AL; Perez CA; Kuban DA; Hancock SL; Smith CD
    JAMA; 1999 May; 281(17):1598-604. PubMed ID: 10235152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
    Zagars GK
    J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.